Shots:
- The P-II ELARA study involves assessing the efficacy & safety of Kymriah in adult patients with r/r FL in 30 sites across 12 countries
- Results: @median follow-up of 11 mos., CRR (66%), ORR (86%) with one-time therapy infusion, median DOR in all responders, PFS & OS were not reached, response rates were consistent across high-risk patient subgroups, estimated DOR in patients with CR and PFS rates @6mos. (94% & 76%), no patient experienced grade 3/4 cytokine release syndrome. The regulatory submissions based on a P-II study is expected in late 2021
- Kymriah is 1st FDA-approved CAR-T cell therapy for r/r ALL in pediatric & adult patients and r/r adult DLBCL
Click here to read full press release/ article | Ref: Globe Newswire | Image: Clinical Trials Arena
The post Novartis Presents Results of Kymriah in P-II ELARA Study for Relapsed or Refractory Follicular Lymphoma at ASCO 2021 first appeared on PharmaShots.
